Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
MoonLake Immunotherapeutics (MLTX) had Return on Tangible Equity of -75.64% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-227.32M |
|
-- |
|
-- |
|
$244.83M |
|
$-244.83M |
|
$15.12M |
|
$-229.71M |
|
$-229.71M |
|
$-230.32M |
|
$-230.32M |
|
$-230.32M |
|
$-230.32M |
|
$-244.83M |
|
$-242.22M |
|
64.46M |
|
64.46M |
|
$-3.53 |
|
$-3.53 |
|
| Balance Sheet Financials | |
$421.69M |
|
$0.58M |
|
$2.74M |
|
$424.43M |
|
$45.48M |
|
$74.10M |
|
$74.47M |
|
$119.95M |
|
$304.48M |
|
$304.48M |
|
$304.48M |
|
71.37M |
|
| Cash Flow Statement Financials | |
$-196.01M |
|
$202.99M |
|
$146.00M |
|
$180.43M |
|
$334.52M |
|
$154.09M |
|
$12.90M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.27 |
|
-- |
|
-- |
|
0.20 |
|
0.24 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-196.04M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-75.64% |
|
|
Return on Tangible Equity |
-75.64% |
-54.27% |
|
-60.84% |
|
$4.27 |
|
$-3.04 |
|
$-3.04 |
|